Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells $423,377.00 in Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider Sukumar Nagendran sold 89,132 shares of Taysha Gene Therapies stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total value of $423,377.00. Following the completion of the sale, the insider directly owned 1,344,307 shares of the company’s stock, valued at $6,385,458.25. This trade represents a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Sukumar Nagendran also recently made the following trade(s):

• On Monday, January 26th, Sukumar Nagendran sold 26,918 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.61, for a total value of $124,091.98.
• On Monday, January 12th, Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.71, for a total transaction of $942,000.00.
• On Friday, November 28th, Sukumar Nagendran sold 110,125 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.75, for a total value of $523,093.75.
• On Monday, December 1st, Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.51, for a total value of $1,172,811.97.

Taysha Gene Therapies Stock Up 2.0%

Shares of NASDAQ TSHA opened at $4.57 on Friday. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $6.02. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48. The stock has a market cap of $1.25 billion, a P/E ratio of -13.85 and a beta of 1.02. The firm has a 50 day moving average price of $5.11 and a 200 day moving average price of $4.09.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Analysts expect that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TSHA. AQR Capital Management LLC lifted its position in Taysha Gene Therapies by 325.6% during the first quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock worth $150,000 after purchasing an additional 82,545 shares during the period. Chicago Partners Investment Group LLC raised its position in shares of Taysha Gene Therapies by 40.5% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 163,766 shares of the company’s stock valued at $378,000 after buying an additional 47,201 shares in the last quarter. Ethic Inc. bought a new stake in shares of Taysha Gene Therapies during the 2nd quarter worth approximately $67,000. Tybourne Capital Management HK Ltd. boosted its position in shares of Taysha Gene Therapies by 10.7% during the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 4,095,000 shares of the company’s stock worth $9,459,000 after acquiring an additional 395,000 shares in the last quarter. Finally, May Hill Capital LLC bought a new position in Taysha Gene Therapies in the second quarter valued at approximately $37,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on TSHA shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 target price on shares of Taysha Gene Therapies in a research report on Friday, October 17th. Wall Street Zen downgraded Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a report on Wednesday, November 5th. Chardan Capital restated a “buy” rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $13.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Taysha Gene Therapies presently has an average rating of “Moderate Buy” and a consensus price target of $10.67.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.